Skip to main content
Longevity Stack
Peptides/Cognitive

Dihexa

Grade C

Animal studies show dramatic effects on spatial memory and synaptic density. No controlled human data exists; safety profile in humans is unknown.

Category
Cognitive
Evidence grade
C
Route
Oral or transdermal (research)
Half-life
Estimated short (oral bioavailability reported)
Typical dose
8–45 mg (anecdotal)
Frequency
Daily
Cycle length
Short cycles only
Best timing
Morning
What researchers are investigating

Cognitive plasticity (preclinical). Animal studies show dramatic effects on spatial memory and synaptic density. No controlled human data exists; safety profile in humans is unknown.

Read the list below as hypotheses, not benefits. This compound is graded C: the effects described come from animal studies, cell work or anecdote — reliable human trials are absent.

  • Synaptogenesis in rodent hippocampus
  • Reversal of scopolamine-induced cognitive deficits (rodents)
  • Reported subjective cognitive enhancement (anecdotal)
Typical dose
8–45 mg (anecdotal)
Frequency
Daily
Route
Oral or transdermal (research)
Evidence
Grade C

Mechanism of Action

Hexapeptide derivative of angiotensin IV. Reported to potentiate hepatocyte growth factor (HGF)/c-Met signaling, promoting synaptogenesis and dendritic spine formation in preclinical models.

Typical Protocol

Dose
8–45 mg (anecdotal)
Frequency
Daily
Duration
Short cycles only
Timing
Morning
Route
Oral or transdermal (research)
Half-life
Estimated short (oral bioavailability reported)

Educational reference only — not medical advice.

Pharmacokinetics & Dosing Rationale

Dihexa is administered oral or transdermal (research) with an approximate systemic half-life of Estimated short (oral bioavailability reported). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Hexapeptide derivative of angiotensin IV. Reported to potentiate hepatocyte growth factor (HGF)/c-Met signaling, promoting synaptogenesis and dendritic spine formation in preclinical models.

How to Administer

  1. Route: Oral or transdermal (research). Typical starting dose 8–45 mg (anecdotal), Daily.
  2. Timing: Morning — keep it the same each dosing day to make effects legible.
  3. Cycle length: Short cycles only. Reassess with bloods and symptom logs before repeating.

Cycling & Stacking Strategy

  • Standard protocol: 8–45 mg (anecdotal), Daily, for Short cycles only.
  • Ramp up: start at the lower end of the dose range for the first 7–10 days to gauge tolerance and side effects before titrating.
  • Break periods let receptor sensitivity and endogenous feedback loops normalise — running back-to-back cycles without a wash-out erodes the effect.
  • Common stack: Omega-3 EPA/DHA, Lion's Mane. Introduce one compound at a time so you can attribute effect and side effect.

Who This Is For

Good candidates
  • Adults with a specific, measurable goal aligned to cognitive plasticity (preclinical).
  • People who already have baseline bloods, a training routine and a sleep protocol in place.
  • Users who can commit to a full cycle, log the protocol, and re-test biomarkers to evaluate response.
  • Anyone working with a clinician willing to supervise off-label or investigational protocols.
Not appropriate for
  • Anyone with active or recent malignancy, or a strong family cancer history where mechanism is angiogenic or growth-promoting.
  • Pregnant or breastfeeding women — human safety data is absent for almost all research peptides.
  • Adolescents and anyone under 21 whose endocrine axis is still developing.
  • People unwilling to run baseline and post-cycle bloods.
  • Specific contraindications for Dihexa: Active or prior malignancy; Pregnancy; Family cancer history.

What to Monitor

Standardised cognitive batteryUse Cambridge Brain Sciences or CANTAB monthly — subjective effects deceive.
Sleep qualityCognitive gains collapse without adequate sleep — track total and REM.
Mood (PHQ-9 / GAD-7)Baseline and every 4 weeks — flag any deterioration early.
Take it with you

Download a printable version of this checklist to log baseline, weekly and post-cycle results.

Reported Benefits

  • Synaptogenesis in rodent hippocampus
  • Reversal of scopolamine-induced cognitive deficits (rodents)
  • Reported subjective cognitive enhancement (anecdotal)

Safety Profile

Side effects
  • Unknown long-term human safety
  • Theoretical proliferative risk via HGF/c-Met
Contraindications
  • Active or prior malignancy
  • Pregnancy
  • Family cancer history
Known interactions
Open interactions explorer →
Tyrosine kinase modulatorsMechanistic overlap with c-Met signaling.

Common Mistakes

  • Chasing a bigger dose instead of consistency — Dihexa outcomes track cumulative exposure, not peak concentration.
  • Skipping baseline bloods, so there is no way to know whether the cycle actually moved a biomarker.
  • Stacking three or four novel compounds at once — you lose the ability to attribute any effect or side effect.
  • Ignoring the training, sleep and nutrition fundamentals that are prerequisites for every peptide protocol.

Evidence Grade — C

Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.

Below are the primary references used to grade Dihexa. Follow the links for full-text where available and cross-check against the current literature.

Frequently Asked Questions

What is the typical Dihexa protocol?+

8–45 mg (anecdotal), Daily, for Short cycles only. Route: Oral or transdermal (research). Timing: Morning. Half-life: Estimated short (oral bioavailability reported).

How does Dihexa work?+

Hexapeptide derivative of angiotensin IV. Reported to potentiate hepatocyte growth factor (HGF)/c-Met signaling, promoting synaptogenesis and dendritic spine formation in preclinical models.

How long before I see results from Dihexa?+

Most users track a full Short cycles only cycle before judging response. Subjective changes can appear within 1–3 weeks, but objective biomarker shifts typically need the full cycle plus repeat labs.

Is Dihexa legal?+

Research chemical. Not approved for human use. Significant unknown oncologic risk.

What are the main side effects of Dihexa?+

Unknown long-term human safety; Theoretical proliferative risk via HGF/c-Met.

What should I stack with Dihexa?+

Commonly combined with: Omega-3 EPA/DHA, Lion's Mane. Introduce one compound at a time to preserve attribution.

What biomarkers should I monitor on Dihexa?+

Baseline and post-cycle: full blood count, comprehensive metabolic panel, and category-specific markers for cognitive peptides (see the monitoring section on this page).

Can I run Dihexa back-to-back?+

Off-cycle periods let receptor sensitivity and endogenous feedback normalise. Continuous dosing without a wash-out typically produces diminishing returns and a poorer safety margin.

References

  1. [1]Dihexa, a potent angiotensin IV analog, augments cognition — Journal of Pharmacology and Experimental Therapeutics, 2012

Further reading: Research library → · Protocols →

Comparison vs Alternatives

Open full comparison →All Peptides →
AttributeDihexaThis pagePinealonTesamorelin
EvidenceGrade CGrade CGrade A
CategoryCognitiveCognitiveGrowth Hormone
Best forCognitive plasticity (preclinical)Cognitive resilience (research)Visceral fat, growth hormone axis
Typical dose8–45 mg (anecdotal)1–10 mg2 mg (1.28 mg for the newer F8/WR formulation)
FrequencyDailyDailyOnce daily
RouteOral or transdermal (research)Intranasal or subcutaneousSubcutaneous injection
Legal statusResearch chemical. Not approved for human use. Significant unknown oncologic risk.Research chemical; not approved for human therapeutic use.FDA-approved as Egrifta and Egrifta SV/WR for HIV-associated lipodystrophy only, and prescription-only. Use for body composition or anti-ageing is off-label. Material sold online as research-grade tesamorelin is not the approved product and carries no purity guarantee.
ActionCurrent pageView →View →